Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

在市场强劲势头推动下，iBio Inc.股价飙升至52周新高，触及5.03美元。对于这家专注于开发和生产植物制药的生物技术公司来说，这一价格水平代表着重要里程碑。根据 InvestingPro 数据显示，该股票的贝塔系数为-3.29，往往与市场趋势相反。过去一年，iBio股价实现了221.37%的显著回报，尤其在过去六个月中表现强劲，涨幅达95.83%。虽然收入增长达650%， ...

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...

(NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed ...

Martin Brenner, Ph.D. “Following more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially ...

Discovered a novel antibody targeting activin E in collaboration with AstralBio, leveraging iBio’s Machine-Learning Antibody Engine to overcome significant technical challenges, demonstrating ...